The Coronary Heart Disease (CHD) template has been updated to include the latest clinical guidance, such as ESC 2024 and NICE QS99 for secondary prevention after MI. There is a focus on the holistic cardiorenal metabolic approach, with specific advice on when to prescribe alternative lipid lowering therapy and semaglutide.The template also features options for social prescribing and support referrals, improved medication review sections, and clearer management pathways as well as a new referral page. All updates aim to make the template more user-friendly and aligned with current best practices.

EMIS version coming soon